Ann: Trofinetide successful in Phase 2 trial in Fragile X, page-21

I will have to go back and look at the Rett results again, but going from memory these look stronger.

I suspect having such a strong response on the Aberrant Behaviour Checklist is a big deal because, if I remember rightly, this is the "standard" metric which has been used across a number of trials.

I suspect the case for Breakthrough will be stronger here than for Rett, both in the general statistical quality and in that the results may conform more closely to the conservative FDA mindset. I will need a day or so of reading to confirm that so treat that as handwaving at this stage, but it's something to consider.